Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationCurrent Price
as of Oct 16, 2024$2.10
P/E Ratio
N/A
Market Cap
$17.9M
GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. It focuses on preventive vaccines against hemorrhagic fever viruses such as Ebola, Sudan, Marburg, and Lassa fever, the Zika virus and malaria, and human immunodeficiency virus, as well as immunotherapies for solid tumor cancers. The company was founded in June 1988 and is headquartered in Smyrna, GA.
Overview
Trading Information
Company